Secukinumab Retention Rates Studied in Psoriasis Patients with or Without GLP-1 RA Co-Therapy
A new real-world study, registered on ClinicalTrials.gov (NCT07881783), is investigating the long-term effectiveness and adherence of secukinumab treatment for moderate-to-severe plaque psoriasis. The research aims to determine if combining secukinumab with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy maintains non-inferior retention rates compared to using secukinumab alone over a period of 12 months.
The study, sponsored by Novartis Pharmaceuticals, is currently active but not recruiting participants. This research is crucial for understanding how the addition of GLP-1 RA affects treatment adherence and long-term outcomes in patients with psoriasis who are already on secukinumab therapy.
Background
Psoriasis is a chronic autoimmune condition that causes red, itchy, scaly patches to appear on the skin. Secukinumab, an interleukin-17A (IL-17A) inhibitor, has been widely used as a biologic treatment for moderate-to-severe psoriasis. However, long-term adherence and retention rates of secukinumab therapy have been variable, with some patients discontinuing due to side effects or lack of efficacy.
The addition of GLP-1 RAs, which are typically used in diabetes management, has shown promise in improving metabolic health and potentially enhancing the therapeutic response in psoriasis. This study seeks to explore whether combining these two treatments can improve patient outcomes without compromising adherence rates.
Key Details
Researchers will monitor treatment retention over a 12-month period for patients who receive secukinumab either alone or in combination with GLP-1 RA therapy. The primary objective is to determine if the combined approach does not result in inferior retention compared to monotherapy use of secukinumab.
Secondary objectives include evaluating adherence patterns, long-term treatment retention, and healthcare resource utilization across both study groups. This comprehensive assessment will provide valuable insights into how adding GLP-1 RA influences patient management strategies for psoriasis.
Key Takeaways
- Non-Inferior Retention: The study aims to confirm that the addition of GLP-1 RA does not reduce retention rates of secukinumab.
- Adherence Patterns: Researchers will analyze adherence behaviors in patients using both therapies versus those on secukinumab alone.
- Healthcare Utilization: Data collected will help understand how combined therapy impacts overall healthcare resource use by psoriasis patients.
- Long-Term Outcomes: The study provides a basis for evaluating the long-term efficacy and safety of combining these treatments.
What This Means
For the peptide community, this research highlights the potential benefits of multi-modal therapeutic approaches in managing chronic conditions like psoriasis. By examining how GLP-1 RA impacts secukinumab treatment retention and adherence, clinicians may be better equipped to tailor personalized care plans that enhance patient outcomes while minimizing side effects.
Moreover, understanding these interactions can pave the way for future studies exploring synergistic effects between different biologics and metabolic agents in treating autoimmune diseases. This could lead to more effective management strategies and improved quality of life for patients suffering from psoriasis and related conditions.
---
Source: ClinicalTrials.gov — Published 2026-11-20
This article is for informational purposes only and does not constitute medical advice.